February 9, 2016 — Boston Scientific Corp. announced the Centers for Medicare and Medicaid Services (CMS) will cover percutaneous left atrial appendage (LAA) closure therapy under specific criteria, as outlined in the agency's final National Coverage Determination (NCD). This decision, effective immediately, provides consistent and uniform access to the Watchman LAA closure Device as a non-pharmacological treatment option for stroke risk reduction for appropriate Medicare beneficiaries.Â
